Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI
Creators
- 1. Department of Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-gu, 03722, Seoul (Korea, Republic of)
- 2. Department of Pathology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul (Korea, Republic of)
- 3. Department of Radiology, Research Institute of Radiological Science, Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul (Korea, Republic of)
- 4. Department of Pathology, National Health Insurance Service Ilsan Hospital, Goyang (Korea, Republic of)
Description
To investigate the imaging findings of macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) on CT and MRI, and examine their diagnostic performance and prognostic significance. We retrospectively enrolled 220 consecutive patients who underwent hepatic resection between June 2009 and December 2013 for single treatment-naïve HCC, who have preoperative CT and gadoxetic acid-enhanced MRI. Independent reviews of histopathology and imaging were performed by two reviewers. Previously reported imaging findings, LI-RADS category, and CT attenuation of MTM-HCC were investigated. The diagnostic performance of the MTM-HCC diagnostic criteria was compared across imaging modalities. MTM-HCC was associated with ≥ 50% arterial phase hypovascular component, intratumoral artery, arterial phase peritumoral enhancement, and non-smooth tumor margin on CT and MRI (p < .05). Arterial phase hypovascular components were less commonly observed on MRI subtraction images than on CT or MRI, while non-rim arterial phase hyperenhancement and LR-5 were more commonly observed on MRI subtraction images than on MRI (p < .05). MTM-HCC showed lower tumor attenuation in the CT arterial phase (p = .01). Rhee's criteria, defined as ≥ 50% hypovascular component and ≥ 2 ancillary findings (intratumoral artery, arterial phase peritumoral enhancement, and non-smooth tumor margin), showed similar diagnostic performance for MRI (sensitivity, 41%; specificity, 97%) and CT (sensitivity, 31%; specificity, 94%). Rhee's criteria on CT were independent prognostic factors for overall survival. The MRI diagnostic criteria for MTM-HCC are applicable on CT, showing similar diagnostic performance and prognostic significance. For MTM-HCC, arterial phase subtraction images can aid in the HCC diagnosis by depicting subtle arterial hypervascularity. MTM-HCC on CT demonstrated previously described MRI findings, including arterial phase hypovascular component, intratumoral artery, arterial phase peritumoral enhancement, and necrosis. The MRI diagnostic criteria for MTM-HCC were also applicable to CT, showing comparable diagnostic performance and prognostic significance. On arterial phase subtraction imaging, MTM-HCC more frequently demonstrated non-rim enhancement and LR-5 and less frequently LR-M than MRI arterial phase, which may aid in the diagnosis of HCC.
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00330-022-09105-7Additional details
Identifiers
Publishing Information
- Journal Title
- European Radiology (Internet)
- Journal Volume
- 33
- Journal Issue
- 2
- Journal Page Range
- p. 1364-1377
- ISSN
- 1432-1084
- CODEN
- EURAE3
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 54030644
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ARTERIES; ATTENUATION; COMPARATIVE EVALUATIONS; COMPUTERIZED TOMOGRAPHY; CONTRAST MEDIA; DATA COMPILATION; DIAGNOSIS; GADOLINIUM COMPOUNDS; HEPATOMAS; HISTOLOGY; IMAGE PROCESSING; LIVER; NECROSIS; NMR IMAGING; REVIEWS; SENSITIVITY; SPECIFICITY; SURVIVAL CURVES
- Descriptors DEC
- BLOOD VESSELS; BODY; CARCINOMAS; CARDIOVASCULAR SYSTEM; DATA; DATA PROCESSING; DIAGNOSTIC TECHNIQUES; DIGESTIVE SYSTEM; DISEASES; DOCUMENT TYPES; EVALUATION; GLANDS; INFORMATION; NEOPLASMS; ORGANS; PATHOLOGICAL CHANGES; PROCESSING; RARE EARTH COMPOUNDS; TOMOGRAPHY